Who Generates More Revenue? Bristol-Myers Squibb Company or Alkermes plc

Revenue Showdown: Bristol-Myers Squibb vs. Alkermes

In the competitive landscape of the pharmaceutical industry, revenue generation is a key indicator of a company's market strength. From 2014 to 2023, Bristol-Myers Squibb Company has consistently outperformed Alkermes plc in terms of revenue. Bristol-Myers Squibb's revenue peaked in 2021 at approximately $46.4 billion, marking a staggering 192% increase from its 2014 figures. In contrast, Alkermes plc, while showing growth, reached its highest revenue in 2023 at around $1.66 billion, reflecting a 169% increase over the same period.

This decade-long analysis highlights Bristol-Myers Squibb's dominant market position, with revenues consistently over 20 times higher than Alkermes. The data underscores the significant scale and reach of Bristol-Myers Squibb in the pharmaceutical sector, while Alkermes continues to carve out its niche with steady growth.